Okunade Kehinde S, John-Olabode Sarah, Ohazurike Ephraim O, Soibi-Harry Adaiah, Osunwusi Benedetto, Anorlu Rose I
Oncology and Pathological Studies (OPS) Unit, Department of Obstetrics and Gynaecology University of Lagos College of Medicine Lagos Nigeria.
Department of Obstetrics and Gynaecology Lagos University Teaching Hospital Lagos Nigeria.
Health Sci Rep. 2022 Jul 7;5(4):e717. doi: 10.1002/hsr2.717. eCollection 2022 Jul.
To improve the overall survival of epithelial ovarian cancer (EOC) patients, a more precise risk identification after completion of standard treatment will enhance patients' follow-up surveillance and the use of individualized targeted therapy.
This study explored the potential risk predictors of early mortality in EOC patients who had standard treatment with debulking surgery and chemotherapy.
The study included 93 EOC patients who had standard treatment and were followed up between January 2011 and December 2020. The sociodemographic, clinical, and laboratory data of patients with EOC including the update on their 3-year follow-up status were retrospectively collected and analyzed. Early mortality is defined as the death of a patient within 3 years of completion of standard treatment. Patients' data were computed using descriptive statistics and the associations between patients' factors and the risk of early mortality were tested using the binary logistic regression model.
Early deaths occurred in 36 (38.7%) of patients with EOC. In the final multivariate analyses, early tumor relapse within 6-months of treatment completion was the only independent risk factor that predicts early mortality in EOC patients (risk ratio = 8.6, 95% confidence interval: 3.3-24.5, < 0.01).
Our study suggests that early tumor relapse may be a useful surrogate of early mortality in EOC. However, our findings should be interpreted with caution pending further corroboration through an adequately powered, prospective multicenter study.
为提高上皮性卵巢癌（EOC）患者的总体生存率，在标准治疗完成后进行更精确的风险识别将加强患者的随访监测并促进个体化靶向治疗的应用。
本研究探讨了接受减瘤手术和化疗标准治疗的EOC患者早期死亡的潜在风险预测因素。
该研究纳入了93例接受标准治疗并在2011年1月至2020年12月期间接受随访的EOC患者。回顾性收集并分析了EOC患者的社会人口统计学、临床和实验室数据，包括其3年随访状态的最新情况。早期死亡定义为患者在标准治疗完成后3年内死亡。使用描述性统计计算患者数据，并使用二元逻辑回归模型测试患者因素与早期死亡风险之间的关联。
36例（38.7%）EOC患者发生早期死亡。在最终的多变量分析中，治疗完成后6个月内的早期肿瘤复发是预测EOC患者早期死亡的唯一独立危险因素（风险比=8.6，95%置信区间：3.3-24.5，P<0.01）。
我们的研究表明，早期肿瘤复发可能是EOC患者早期死亡的一个有用替代指标。然而，在通过充分有力的前瞻性多中心研究得到进一步证实之前，我们的研究结果应谨慎解读。
